Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Diabetes
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Diabetes
    Darbepoetin Alfa Risks Outweigh Benefits for Patients With CKD, Diabetes, and Anaemia: Presented at Renal Week 2009 - (DGDispatch)
    Fenofibrate May Protect Diabetics Against Loss of Renal Function: Presented at Renal Week 2009 - (DGDispatch)
    A Trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney Disease - (N Engl J Med)
    TopAbstracts in Diabetes 11/03/2009 - (DGNews)
    Paricalcitol Added to Hypertension Therapy Lowers Albuminuria in Patients With Diabetes and Chronic Kidney Disease: Presented at Renal Week 2009 - (DGDispatch)

    News archive

     Recent webcasts/CME - Diabetes
    • Optimizing Insulin-Dependent Diabetes Management in Long-Term Care
    • Insulin-Dependent Diabetes in Long-Term Care: Scope of the Problem and Effective Management
    • Cases in Practice: Incretin-Based Therapies for Common Patient Encounters
      Diabetes Management - Pearls of Lipid Control
      Obesity Management in Patients with Type 2 Diabetes

      Webcasts/CME archive

       Recent cases - Diabetes
        Acquired Perforating Dermatosis: Association with Diabetes and Renal Failure
        A Patient Presenting with Symptomatic Hypomagnesemia Caused by Metformin-Induced Diarrhoea: A Case Report
        Absence of Diabetic Retinopathy in a Patient who has had Diabetes Mellitus for 69 Years, and Inadequate Glycemic Control: Case Report
        Gallbladder Edema in Type 1 Diabetic Patient due to Delayed-type Insulin Allergy
        Compound Heterozygous Mutation of Aquaporin 2 Gene in Woman Patient with Congenital Nephrogenic Diabetes Insipidus

        Cases archive
          




        my personal edition > diabetes > news
        divider

          E-Mail this DGDispatch to a colleague

        DGDispatch


        Women Gain More Weight Than Men When Taking Thiazolidinedione: Presented at AACE

        By Mike Fillon

        CHICAGO, I.L. -- May 3, 2006 -- Women with type 2 diabetes gain more weight than men do after initiation of thiazolidinedione therapy, according to results of a study presented here at the American Association of Clinical Endocrinologists (AACE) 15th annual meeting.

        It is important for people to know that weight gain is a potential effect of treatment with these drugs, and women in particular are not informed that they have an increased risk of gaining weight compared to a male patient, said lead researcher Amy Toscano-Zukor, DO, a third-year internal medicine resident at Saint Peter's University Hospital, New Brunswick, New Jersey, in his presentation on April 27th. "It also might help them pinpoint a possible cause for weight gain," Dr. Toscano-Zukor said.

        In the study, the researchers randomly reviewed the charts of 100 outpatients in an endocrinology practice who had received or were receiving the thiazolidinediones pioglitazone or rosiglitazone as either monotherapy or as part of a multi-drug regiment for diabetes mellitus therapy.

        The researchers analyzed patients' weight as recorded in the charts during office visits to identify any subsequent changes since the initiation or discontinuation of thiazolidinediones. Records were also analyzed for any patient-reported weight changes during treatment prior to the study.

        Patients who gained weight and those who did not gain weight were compared according to the following characteristics: gender, body weight, body mass index (BMI), duration of diabetes, most recent hemoglobin A1C (HbA1c) level, and concomitant use of insulin, metformin and sulfonylureas.

        Significant weight gain was defined as >3% weight increase from baseline, >3% weight loss after the thiazolidinedione was discontinued, or >10% patient-reported weight increase since initiation of thiazolidinedione therapy.

        Patients were divided into 2 groups for comparison: Weight-gainers and non-weight-gainers. Among the 100 consecutive patients treated with thiazolidinediones, 52 gained significant weight. There were more women in the group of weight-gainers compared to the group of non-weight-gainers (63.5% vs. 37.5%, P <.05).

        There was no significant difference between weight gainers and non-weight gainers in terms of age, body weight, BMI, duration of diabetes, most recent HbA1c and combination therapy with insulin, metformin, or sulfonylureas..

        Dr. Toscano-Zukor said that while no one is sure why women are more apt to gain weight when taking thiazolidinediones, one theory is that the proposed fat distribution that occurs with these agents is more pronounced in females because of their preexisting larger ratio of subcutaneous to visceral fat.


        [Presentation title: Comparing Characteristics of Weight-Gainers to Non-Weight Gainers With Diabetes Mellitus Treated With Thiazolidinediones. Abstract 246]



        E-Mail this DGDispatch to a colleague   To print, use this version






        All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send